Inappropriate Medications Associated With Anticholinesterase and/or Memantine Treatment in the Elderly
- Conditions
- Alzheimer's Disease
- Registration Number
- NCT00954616
- Lead Sponsor
- University Hospital, Limoges
- Brief Summary
In each of the 7 French areas that should be involved, patients aged 75 years and over from three different sectors will be included: the geriatric consultation unit (60%) and two kinds of nursing homes, private (20%) and state (10%). Outpatients will be included in chronological order; patients in nursing homes will be included at random. The patients and their families will be asked about the treatments received on the day of inclusion. The inclusion period will extend over a year. The investigating practitioners will be asked to fill in a questionnaire reporting the main clinical data, adverse effects occurrence, and information on the treatment given.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 636
- Patients aged 75 years and over identified as having Alzheimer disease and who have been treated for more than 3 months with anticholinesterase and/or memantine
- Patients with decompensated chronic condition or acute phase disease
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate the prevalence of PIM use in patients aged 75 years and over treated with anticholinesterase and/or memantine 2 years
- Secondary Outcome Measures
Name Time Method To identify factors associated with PIM use. To study the relationship between PIM exposure and adverse effects occurrence. 2 years
Trial Locations
- Locations (6)
CHU Rouen
🇫🇷Rouen, Bois guillaume, France
CHU Bordeaux
🇫🇷Pessac, Bordeaux, France
CHU Saint Etienne
🇫🇷Saint Etienne, France
CH Le Mans
🇫🇷Le Mans, Le Mans Cedex 1, France
CHU Montpellier
🇫🇷Montpellier, Montpellier Cedex 5, France
APHP Charles Foix
🇫🇷Ivry sur Seine, Paris, France